text.skipToContent text.skipToNavigation
Integrated Biologics
Advanced Synthesis
Specialized Modalities

Faster growth for HEK293 cell expansion

Across four different HEK293 cell lines, TheraPEAK 293-GT® Media System supports robust cell growth. Some cell lines experienced up to 59% higher density after 5 days in TheraPEAK 293-GT® Media System than in their cloning/adaptation media.

TheraPEAK 293-GT® Media System maintained a high viability of ≥95% across the same four different HEK293 cell lines, demonstrating a superior ability to support proliferation needed for AAV production.

TheraPEAK 293-GT® Media System cell growth and culture viability

Growth and viability curves for 4 different cell lines in TheraPEAK 293-GT® Medium

TheraPEAK 293-GT® AAV Supplement high titer

Graph demonstrating the synergistic effect to increase AAV titer with TheraPEAK 293-GT® AAV Supplement.

How to increase AAV titer, the first time

Addition of TheraPEAK 293-GT® AAV Supplement during transfection supports increased AAV titer as compared to using a commercial enhancer alone. Here, use of the complete TheraPEAK 293-GT® Media System delivers a ~3x increase in AAV titer whereas a commercial enhancer alone delivers only a ~2x increase above baseline performance.

Increased AAV titer versus a leading HEK293 media

TheraPEAK 293-GT® Media System is designed for high-titer AAV production across multiple viral serotypes. It outperforms a leading HEK293 media for AAV production in a direct comparison and achieves titers as high as 1e12 vg/mL through process development with a commercial enhancer.

TheraPEAK 293-GT® Media System versus a competitor AAV media

Graph demonstrating increased AAV titer with TheraPEAK 293-GT® Media System versus a leading AAV media.

TheraPEAK 293-GT® Media System high titer and capsid flexibility

Graph demonstrating the broad compatibility of TheraPEAK 293-GT® Media System to deliver high titer and favorable full capsid ratios.

How to deliver robust AAV titer and full capsid ratio across a variety of platforms

TheraPEAK 293-GT® Media System helps deliver favorable AAV titer and full capsid ratios across multiple transfection reagents, enhancers, and viral serotypes, making it ideal for commercial AAV production.

Help outperform “out-of-the-box” systems and improve full capsid ratio

Basic process development for AAV production with TheraPEAK 293-GT® Media System generated an increased AAV titer and improved full capsid ratio versus the leading competitor AAV platform kit, and at a potentially lower total production cost.


 

Do you need manufacturing services?

We are your CDMO partner for CGT development and manufacturing needs.

TheraPEAK 293-GT® Media System versus a leading AAV production kit

Graph demonstrating increased AAV titer and full capsid ratio with TheraPEAK 293-GT® Media System versus a leading AAV production kit.

Questions? We've got answers

Find answers to commonly asked questions about our TheraPEAK 293-GT® Media System for suspension HEK293-derived cell lines

Can the media system be used for production of modalities other than AAV, with producer cell lines (PCLs), or in cell lines other than HEK293?

Our media system was developed for use in suspension HEK293 cell lines for triple-transfection AAV production. Our research data suggests limited use cases for protein production or in other cell lines.

Are TheraPEAK 293-GT® Medium and AAV Supplement sold separately?

No, the two components of TheraPEAK 293-GT® Media System are designed to work together to increase AAV titer.

How does our media system compare to other AAV production media on the market?

Download our application note or product sheet to see cell growth, cell viability, viral titer and viral capsid data for our media system as compared to the industry leading complete production kit and the industry leading media for AAV production.

Does our media system work with different transfection reagents?

Yes! Download our application note or product sheet to see favorable performance of our media system with 2 different commercially available transfection reagents.

What is the largest scale you have tested for your media system?

Our media system has been tested up to a 3-L scale and demonstrated viral titer and capsid packaging performance comparable to the research scale (125-mL flask) reported in our technical materials.

Do you have documentation supporting the non-animal origin (NAO) of your media system components?

Yes, contact our scientific support team if you require an NAO statement.

Are any components of your media system formulation classified as toxic?

No, our media system contains no toxic components. Contact our scientific support team if you require a toxicity statement.

Does the media system contain phenol red?

No, our media system does not contain phenol red.

Should I add any nutritional supplementation to your media system to support cell growth?

It is not necessary to add nutritional supplementation because Tour media system is preformulated for cell growth, viability, and AAV production, however if your process uses an alternative nutritional source you can add any supplementation required.